Currently out of the existing stock ratings of Roy Buchanan, 88 are a BUY (96.7%), 3 are a HOLD (3.3%).

Roy Buchanan

Work Performance Price Targets & Ratings Chart

Analyst Roy Buchanan, carries an average stock price target met ratio of 31.46% that have a potential upside of 50.21% achieved within 132 days. Previously, Roy Buchanan worked at JMP.

Roy Buchanan’s has documented 167 price targets and ratings displayed on 15 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CDTX, Cidara Therapeutics at 21-Oct-2025.

Wall Street Analyst Roy Buchanan

Analyst best performing recommendations are on CDTX (CIDARA THERAPEUTICS).
The best stock recommendation documented was for CDTX (CIDARA THERAPEUTICS) at 6/2/2025. The price target of $47 was fulfilled within 23 days with a profit of $24.33 (107.32%) receiving and performance score of 46.66.

Average potential price target upside

of $84.7 (24.34%) on ARGX (ARGENX NV ADR).
of $28.32 (74.54%) on CDTX (CIDARA THERAPEUTICS).
of $18.07 (36.23%) on ENTA (ENANTA PHARMACEUTICALS).

CVAC CureVac NV ENTA Enanta Pharmaceuticals HOOK Hookipa Pharma ARGX argenx NV ADR ABUS Arbutus Biopharma Corp DVAX Dynavax Technologies IBIO Ibio PRDS Pardes Biosciences ANTX AN2 Therapeutics GRTS Gritstone Oncology ESPR Esperion Therapeutics INO Inovio Pharmaceuticals CDTX Cidara Therapeutics PYPD PolyPid DVA DaVita HealthCare Partners

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Eliana Merle (UBS)